Kondo, Hideomi http://orcid.org/0000-0002-2860-8048
Okimoto, Nobukazu
Yoshioka, Toru
Akahoshi, Shojiro
Fuse, Yoshifumi
Ogawa, Takayuki
Okazaki, Yuichi
Katae, Yuji
Tsukamoto, Manabu
Yamanaka, Yoshiaki
Kawasaki, Makoto
Sakai, Akinori
Article History
Received: 27 April 2020
Accepted: 30 June 2020
First Online: 12 July 2020
Compliance with ethical standards
:
: H. Kondo, T. Yoshioka, S. Akahoshi, Y. Fuse, T. Ogawa, Y. Okazaki, Y. Katae, M. Tsukamoto, Y. Yamanaka and M. Kawasaki declare they have no conflict of interest. N. Okimoto has received consulting fees from Asahi-Kasei Pharmaceutical Co., Ltd and Teijin Pharma Ltd, and payments have been made to lectures, including speakers’ bureau fees, from Asahi-Kasei Pharmaceutical Co., Ltd.; Amgen Astellas BioPharma K.K.; Astellas Pharma Inc.; Chugai Pharmaceutical Co.; Daiichi-Sankyo Co. Ltd.; Eisai Co., Ltd.; Eli Lilly Japan K.K.; Mitsubishi-Tanabe Pharma Corp.; Ono Pharmaceutical Co.; Pfizer Japan Inc.; and Teijin Pharma Ltd, for outside the submitted work. A. Sakai has received grants from Asahi-Kasei Pharmaceutical Co., Ltd. and Chugai Pharmaceutical Co., Ltd., during the conduct of this study, and personal lecture fees were received from Asahi-Kasei Pharmaceutical Co., Ltd. and Chugai Pharmaceutical Co., Ltd., for outside the submitted work.
Free to read: This content has been made available to all.